Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma

BACKGROUND: In this era of developing targeted therapies and immunotherapies as a treatment for renal cell carcinoma (RCC), Programmed death ligand 1 (PDL1) as a novel biomarker for RCC is analysed in our study. About 90% of all renal cancers are Renal Cell Carcinoma. Most cases are diagnosed incide...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekaran, Deepika, Sundaram, Sandhya, N, Kadhiresan, R, Padmavathi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982669/
https://www.ncbi.nlm.nih.gov/pubmed/31653140
http://dx.doi.org/10.31557/APJCP.2019.20.10.2951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982669/
https://www.ncbi.nlm.nih.gov/pubmed/31653140
http://dx.doi.org/10.31557/APJCP.2019.20.10.2951

Ejemplares similares